# Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers

> **NCT05278195** · — · UNKNOWN · sponsor: **Zhongda Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05278195
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278195, "Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05278195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*